Bonum Medelae Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 14 Year, 21 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.70 M
as on 16-11-2024
- Revenue 5.49%
(FY 2023)
- Profit 11.33%
(FY 2023)
- Ebitda 22.19%
(FY 2023)
- Net Worth 3.11%
(FY 2023)
- Total Assets 0.26%
(FY 2023)
About Bonum Medelae
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.70 M.
Sukhdeep Kaur, Jasmeet Sandhu, Upender Jindal, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232HR2010PTC041647
- Company No.
041647
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Dec 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Ambala, Haryana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Bonum Medelae Private Limited offer?
Bonum Medelae Private Limited offers a wide range of products and services, including Aceclofenac Tablet, Aceclofenac Paracetamol Chlorzoxazone Tablet, Vitamin Tablets & Capsules, Thiamine Hydrochloride, Pantoprazole Drugs, Pantoprazole Sodium Injection, Diclofenac, Diclofenac Sodium Injection, Aceclofenac Paracetamol Serratiopeptidase Tablet, Antifungal Injection, Tablet & Syrup.
Who are the key members and board of directors at Bonum Medelae?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jaskaran Sandhu  | Director | 02-Dec-2010 | Current |
| Sukhdeep Kaur | Director | 17-Aug-2016 | Current |
| Jasmeet Sandhu | Director | 25-Feb-2022 | Current |
| Upender Jindal | Director | 25-Feb-2022 | Current |
| Gurinder Singh | Director | 02-Dec-2010 | Current |
Financial Performance of Bonum Medelae.
Bonum Medelae Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 5.49% increase. The company also saw a substantial improvement in profitability, with a 11.33% increase in profit. The company's net worth moved up by a moderate rise of 3.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bonum Medelae?
In 2023, Bonum Medelae had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 10 Jan 2024 | ₹2.70 M | Open |
How Many Employees Work at Bonum Medelae?
Unlock and access historical data on people associated with Bonum Medelae, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bonum Medelae, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bonum Medelae's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
